Fulgent Genetics, Inc. (FLGT)
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
$19.73+0.41%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Diagnostics & ResearchSnapshot 2026-09-04
Intact: The reason to own it still holds.
Fulgent Genetics aims for $350 million revenue in 2026. It holds $636 million in cash and investments. The company has completed acquisitions to expand its services. Recent earnings beats show some operational strength.
The company is loss-making with EPS guidance near -$1.59 in 2026. Revenue growth is modest and below high-growth peers. Profit margins remain weak and free cash flow is negative.
The price is about 17% below our fair value near $26. Analysts expect roughly 17% revenue growth. Our view aligns with cautious optimism given the turnaround risks.
Breaks if: cash and investments fall below $600 million in FY26
Breaks if: EPS falls below -$1.7 in FY26
Breaks if: annual revenue falls below $325 million in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a turnaround scenario. The company is currently facing operational difficulties and has reported weak financial performance, but it operates in a sector that has favorable momentum.
The market seems to have priced in a low expectations gap, indicating that investors are not anticipating significant positive developments. FLGT's valuation is considered cheap compared to its peers, suggesting that there may be room for improvement if the company can execute on its plans.
Management has set ambitious revenue targets but has recently revised guidance downward due to operational challenges. The therapeutic pipeline shows promise, but financial results have not yet reflected this progress, indicating a mixed outlook.
The long-term thesis hinges on FLGT's ability to meet revised revenue targets and successfully integrate its recent acquisition. Additionally, the performance of sector leaders may influence FLGT's trajectory, especially if they continue to show strong results.
The most important moves since the prior daily snapshot.
Valuation fell by 28.4 points (from 59.6 to 31.2).
Signal changed from 'mild_favorable' to 'mixed'.
Composite insight fell by 10.3 points (from 13.2 to 2.9).
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain revenue growth to reach approximately $350 million in total revenue for fiscal year 2026.
In the next 1 to 3 years, FLGT's performance will depend on its operational execution and sector dynamics. Not investment advice.
Review the evidence to watch, what would become a concern, and what would make it less concerning.